Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | FABP1 | P07148 | 1/20 | 0.38 |
| ▸ | FABP6 | P51161 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | RAD52 | P43351 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5033376 | 0.76 | GSK3B (0.54) | HTTKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL7703948 | 0.73 | MEN1 (0.45) | MAOAKMT2AMEN1THRBTDP1 | |
| SCHEMBL15844125 | 0.68 | HSD17B10 (0.40) | HSD17B10HTTMAOAFABP1FABP6 | |
| SCHEMBL218277 | 0.65 | MAOA (0.39) | HSD17B10MAOATDP1ALDH1A1CYP1A2 | |
| SCHEMBL3374310 | 0.65 | POLB (0.48) | HSD17B10HTTFABP1FABP6KMT2A | |
| N-Benzylaniline SCHEMBL7840 | 0.64 | HTT (0.71) | HTTKMT2AMEN1ALDH1A1CYP1A2 | |
| SCHEMBL1924100 | 0.64 | HTT (0.78) | HTTKMT2AMEN1ALDH1A1CYP1A2 | |
| SCHEMBL22628164 | 0.64 | HTT (0.71) | HTTKMT2AMEN1ALDH1A1CYP1A2 | |
| SCHEMBL4571036 | 0.64 | HSD17B10 (0.71) | HSD17B10HTTFABP1FABP6KMT2A | |
| SCHEMBL30464743 | 0.64 | HSD17B10 (0.71) | HSD17B10HTTFABP1FABP6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2678079-B1 | OXIDATIVE DYEING COMPOSITIONS COMPRISING AN 1-HEXYL/HEPTYL-4,5-DIAMINOPYRAZOLE AND A BENZO[1,3]DIOXOL-5-YLAMINE AND DERIVATIVES THEREOF | NOXELL CORP (US) | 2017-08-02 | — | — | EP | claimed |
| WO-2013085553-A2 | OXIDATIVE DYEING COMPOSITIONS COMPRISING AN 1-HEXYL/HEPTYL-4,5-DIAMINOPYRAZOLE AND A BENZO[1,3]DIOXOL-5-YLAMINE AND DERIVATIVES THEREOF | THE PROCTER & GAMBLE COMPANY (US) | 2013-06-13 | — | — | WO | claimed |
| US-8444712-B2 | Oxidative dyeing compositions comprising an 1-hexyl/heptyl-4,5-diaminopyrazole and a benzo[1,3]dioxol-5-ylamine and derivatives thereof | THE PROCTER & GAMBLE COMPANY (US) | 2013-05-21 | — | — | US | claimed |
| US-20120210521-A1 | Oxidative Dyeing Compositions Comprising an 1-Hexyl/Heptyl-4,5-diaminopyrazole and a Benzo[1,3]dioxol-5-ylamine and Derivatives Thereof | WELLA OPERATIONS US, LLC | 2012-08-23 | — | — | US | claimed |
| EP-2678079-B1 | OXIDATIVE DYEING COMPOSITIONS COMPRISING AN 1-HEXYL/HEPTYL-4,5-DIAMINOPYRAZOLE AND A BENZO[1,3]DIOXOL-5-YLAMINE AND DERIVATIVES THEREOF | NOXELL CORP (US) | 2017-08-02 | — | — | EP | disclosed |
| US-9365582-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2016-06-14 | — | — | US | disclosed |
| EP-1799684-B1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARM INC (US) | 2014-12-03 | — | — | EP | disclosed |
| US-20140113929-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | Janssen R&D Ireland (formerly Tibotec Pharmaceuticals) (IE) | 2014-04-24 | — | — | US | disclosed |
| US-8637663-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN R&D IRELAND (IE) | 2014-01-28 | — | — | US | disclosed |
| EP-2418205-B1 | Pyrimidine urea derivatives as kinase inhibitors | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| CN-103458863-A | Oxidative dyeing composition comprising 1-hexyl/heptyl-4,5-diaminopyrazole and benzo[1,3]dioxol-5-ylamine and derivatives thereof | PROCTER & GAMBLE | 2013-12-18 | — | — | CN | disclosed |
| CN-103458863-A | Oxidative dyeing composition comprising 1-hexyl/heptyl-4,5-diaminopyrazole and benzo[1,3]dioxol-5-ylamine and derivatives thereof | PROCTER & GAMBLE | 2013-12-18 | — | — | CN | disclosed |
| WO-2002079144-A1 | (P-AMINO-HYDROXYPHENYL)-ACRYLAMIDE DERIVATIVES AND DYES CONTAINING SAID COMPOUNDS | WELLA AKTIENGESELLSCHAFT (DE) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002074731-A1 | 3-(2,5-DIAMINOPHENYL)-ACRYLAMIDE DERIVATIVES AND COLOURING AGENTS CONTAINING SAID COMPOUNDS | WELLA AKTIENGESELLSCHAFT (DE) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002072556-A1 | NOVEL DIAMINOPYRAZOLE DERIVATIVES AND DYES CONTAINING SAID COMPOUNDS | WELLA AKTIENGESELLSCHAFT (DE) | 2002-09-19 | — | — | WO | disclosed |
| US-6410529-B1 | DIETETICS; NON-INSULIN DEPENDENT DIABETES; SLEEP DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-06-25 | — | — | US | disclosed |
| EP-1030838-A1 | METHOD OF SYNTHESIS OF PYRROLE AMIDES | Pfizer Products Inc. (US) | 2000-08-30 | — | — | EP | disclosed |
| EP-1003737-A1 | PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS HFGAN72 ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999025684-A1 | METHOD OF SYNTHESIS OF PYRROLE AMIDES | PFIZER PRODUCTS INC. (US) | 1999-05-27 | — | — | WO | disclosed |
| WO-1999009024-A1 | PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS HFGAN72 ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1999-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120210521-A1 | Oxidative Dyeing Compositions Comprising an 1-Hexyl/Heptyl-4,5-diaminopyrazole and a Benzo[1,3]dioxol-5-ylamine and Derivatives Thereof | KRT18, HK1, AOX1 | HSD17B10 2421/4885HTT 2037/4885MAOA 388/4885 |
| US-20140113929-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | HCCS, HAVCR2, IFNAR1 | HSD17B10 536/4885HTT 3567/4885MAOA 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.